Zevra Therapeutics, Inc. (ZVRA)
NASDAQ: ZVRA · Real-Time Price · USD
8.90
-0.26 (-2.84%)
Mar 30, 2026, 10:42 AM EDT - Market open
Zevra Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Zevra Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $23, which forecasts a 158.43% increase in the stock price over the next year. The lowest target is $18 and the highest is $26.
Price Target: $23 (+158.43%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Zevra Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 3 | 3 |
| Buy | 3 | 3 | 3 | 3 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Initiates $23 | Strong Buy | Initiates | $23 | +158.43% | Mar 16, 2026 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $25 → $24 | Strong Buy | Maintains | $25 → $24 | +169.66% | Nov 6, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $29 → $24 | Buy | Maintains | $29 → $24 | +169.66% | Nov 6, 2025 |
| JMP Securities | JMP Securities | Buy Maintains $19 → $18 | Buy | Maintains | $19 → $18 | +102.25% | Aug 13, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $25 → $29 | Buy | Maintains | $25 → $29 | +225.84% | Jul 10, 2025 |
Financial Forecast
Revenue This Year
146.15M
from 106.47M
Increased by 37.27%
Revenue Next Year
224.22M
from 146.15M
Increased by 53.42%
EPS This Year
0.57
from 1.35
Decreased by -58.07%
EPS Next Year
1.64
from 0.57
Increased by 189.32%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 176.4M | 354.4M | |||
| Avg | 146.2M | 224.2M | |||
| Low | 131.9M | 174.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 65.7% | 142.5% | |||
| Avg | 37.3% | 53.4% | |||
| Low | 23.9% | 19.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.12 | 2.96 | |||
| Avg | 0.57 | 1.64 | |||
| Low | 0.28 | 0.97 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -16.8% | 423.1% | |||
| Avg | -58.1% | 189.3% | |||
| Low | -78.9% | 71.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.